Chinese medical journal
-
Chinese medical journal · Jul 2023
Meta AnalysisRisk of second primary lung cancer in patients with thyroid cancer: a meta-analysis based on big population studies.
Previous studies have revealed that the number of cancer survivors developing a second primary malignancy is increasing, especially among thyroid cancer patients, and lung cancer is still the main cause of cancer death. Therefore, we aimed to investigate the risk of second primary lung cancer (SPLC) in patients with thyroid cancer. ⋯ International Prospective Register of Systematic Reviews: No. CRD42021285399.
-
Chinese medical journal · Jul 2023
ReviewImmune checkpoint inhibitors for the treatment of non-small cell lung cancer brain metastases.
Lung cancer has the highest risk of brain metastasis (BM) among all solid carcinomas. The emergence of BM has a significant impact on the selection of oncologic treatment for patients. Immune checkpoint inhibitors (ICIs) are the most promising treatment option for patients without druggable mutations and have been shown to improve survival in patients with non-small cell lung cancer (NSCLC) BM in clinical trials with good safety. ⋯ According to studies pertaining to tumor immune microenvironments, ICIs may be capable of provoking immunity in situ. Meanwhile, systematic immune cells activated by ICIs can migrate into the central nervous system and exert antitumor effects. This review summarizes the present evidence for ICI treatment efficacy in NSCLC BM and proposes the possible mechanisms of ICI treatment for NSCLC BMs based on existing evidence.
-
Chinese medical journal · Jul 2023
Meta AnalysisSuperiority of sugammadex in preventing postoperative pulmonary complications.
Postoperative pulmonary complications often lead to increased mortality and financial burden. Residual paralysis plays a critical role in postoperative pulmonary complications. This meta-analysis was performed to determine whether sugammadex overmatches neostigmine in reducing postoperative pulmonary complications. ⋯ PROSPERO ( https://www.crd.york.ac.uk/PROSPERO/ ); CRD 42020191575.